A
Alkermes plc (ALKS)
NMS – Real vaqt narxi. Valyuta: USD
38.29
+2.82 (7.95%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
38.29
+2.82 (7.95%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Alkermes plc, biopharmaceutical kompaniyasi, Qo'shma Shtatlar, Irlandiya va xalqaro miqyosda terapevtik sohalarda bemorlarning qondirilmagan tibbiy ehtiyojlarini qondirish uchun farmatsevtika mahsulotlarini tadqiq qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya o'zining giyohvandlikka bog'liqlik, alkogolga bog'liqlik, shizofreniya, bipolyar I buzilishi va nevrologik kasalliklar uchun ishlab chiqilayotgan klinik va preklinik mahsulot nomzodlari portfeliga ega. Uning sotilayotgan mahsulotlari orasida shizofreniyani davolash uchun mushak ichiga yuboriladigan in'ektsion suspenziya bo'lgan ARISTADA; kattalar uchun shizofreniyani davolash uchun ARISTADA INITIO; alkogolga bog'liqlikni davolash va giyohvandlikka bog'liqlikning oldini olish uchun VIVITROL; shizofreniya va bipolyar I buzilishi bilan og'rigan kattalarni davolash uchun og'iz orqali qabul qilinadigan atipik antipsikotik dori nomzodi bo'lgan LYBALVI; va bolalarda katalepsiya yoki EDSni davolash uchun uzaytirilgan chiqariladigan og'iz suspenziyasi mahsuloti bo'lgan LUMRYZ mavjud. Kompaniya, shuningdek, uchinchi tomonlarga mahsulotlarni ishlab chiqish, tijoratlashtirish va ishlab chiqarish imkonini beradigan o'ziga xos texnologik platformalarini taklif etadi. U asosan Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc va Janssen Pharmaceutica International bilan hamkorlik shartnomalariga ega. Alkermes plc 1987 yilda tashkil etilgan va shtab-kvartirasi Dublin, Irlandiyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Craig C. Hopkinson M.D. | Executive VP of Research & Development and Chief Medical Officer |
| Mr. Blair C. Jackson | Executive VP, Chief Risk Officer & COO |
| Mr. Christian Todd Nichols | Senior VP & Chief Commercial Officer |
| Mr. David Joseph Gaffin J.D. | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary |
| Mr. Joshua Reed M.B.A. | Senior VP & CFO |
| Mr. Richard F. Pops | Chairman & CEO |
| Mr. Samuel J. Parisi | Interim Principal Accounting Officer & VP of Finance |
| Mr. Stephen Schiavo | Senior VP & Chief Human Resources Officer |
| Mr. Tom Skoff | SVP & Chief Information Officer |
| Ms. Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 8-K | alks-20260505.htm |
| 2026-05-01 | 8-K/A | alks-20260212.htm |
| 2026-04-06 | DEF 14A | alks-alks_2026_def_14a.pdf |
| 2026-03-27 | PRE 14A | alks-20260327.htm |
| 2026-02-25 | 10-K | alks-20251231.htm |
| 2026-02-12 | 8-K | d43532d8k.htm |
| 2026-01-12 | 8-K | alks-20260112.htm |
| 2026-01-06 | 8-K | alks-20260106.htm |
| 2025-11-19 | 8-K | d858713d8k.htm |
| 2025-11-12 | 8-K | alks-20251112.htm |